Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RAIN - Rain Oncology Inc.

Close
1.23
1.230   100.000%

Share volume: 0
Last Updated: Thu 25 Jan 2024 09:08:04 PM CET
Medicinal and Botanical Manufacturing : 1.15%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
50%
Profitability 40%
Dept financing 18%
Liquidity 25%
Performance 75%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
-81.36%
Key data
Stock price
$1.23
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.21 - $1.27
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
27.580 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Avanish Vellanki
Region: US
Website: rainthera.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Medicinal and Botanical Manufacturing
Sector: Manufacturing

Rain Therapeutics Inc. engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2. The company is also developing RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers.

Recent news